Opinion|Videos|October 18, 2024
Addressing Unmet Needs in ART
Author(s)Jeffrey Dunn, PharmD, MBA
Jeffrey Dunn, Pharm.D., MBA, discusses how key unmet needs in assisted reproductive technology (ART) programs drive ongoing research and innovation, fostering hope for a future where fertility treatments are more effective, accessible and tailored to individual patient needs.
Advertisement
Episodes in this series
Advertisement
Related to this article
Christine Johnston says Medicaid plans have embraced biosimilars faster than commercial plans and challenges the idea that more expensive means better.
After more than 20 years at Humana, Jeremy Gaskill now leads nonprofit Geisinger Health Plan. The problems are the same, he says, the scale for solving them differs.
Jeremy Gaskill took the reins at the Geisinger Health Plan earlier this year after a long career at Humana. He discusses the similarities and differences between Geisinger and Humana and the advantages of a health plan that is part of a health system.
The retail pharmacies will be in one company and Aetna and CVS Caremark, the PBM, in another, according to news reports.
Christine Johnston warns a thin biosimilar pipeline keeps specialty costs high and slows innovation and urges payers to check their PBM’s top 25 drugs.
Speakers and researchers at this year's meeting in San Diego focused on drug pricing policy, getting savings to patients at the pharmacy counter and keeping people in charge of AI.
The generic twice-yearly HIV prevention shot is expected to cost $40 a year in 120 countries, 16 months after Gilead's original approval.
Annual healthcare costs jump by almost $25,000 with targeted therapy for atopic dermatitis that avoided costs from reduced hospitalizations and ER visits only partly offset, according to recently reported research findings.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
CVS Health is splitting in two, according to news reports
2
Christine Johnston on the biosimilar pipeline and PBM formularies
3
From MFP fallout to AI guardrails: What stood out at AMCP Nexus 2026
4
FDA tentatively approves first generic lenacapavir for HIV prevention in lower-income countries
5